Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Breast Cancer: Locally Advanced Disease

August 12, 2015

Join Kathleen Horst, MD and Melinda Telli, MD as they present their multidisciplinary expertise on a range of cases pertaining to locally advanced disease breast cancer.

Breast cancer continues to be the second leading cause of cancer death in women, exceeded only by lung cancer. Due to the complexity of care involved, it is very important for the multidisciplinary cancer team (consisting of a surgeon, pathologist, radiation oncologist, medical oncologist) to coordinate not only with each other but also with primary care physicians and specialist care teams to implement and deliver comprehensive, efficient, and patient-centered care.   Selecting the most efficient systemic therapy approach for locally advanced disease is based not only on patient characteristics (comorbidities), tumor characteristics (size, nodal status) but also heavily on tumor biomarkers (ER, PR, and HER2). Therefore, the clinicians need to be aware of the importance of accurate assessment of the status of tumor biomarkers.  With respect to neoadjuvant/adjuvant systemic therapy, the results of recent trials have led to approval of new agents and new therapeutic strategies.  The clinicians need to stay up-to-date with the continuously evolving standard-of-care.

Target Audience

This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Use biomarkers and patient characteristics to assess risk and individualize therapeutic strategies
  • Outline evidence-based adjuvant treatment options available for patients with locally advanced breast cancer
Additional information

This activity is supported by educational grants from:

  • BTG
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Genomic Health, Inc.
  • Lilly
  • Merck
  • Novartis Oncology
  • Prometheus Laboratories, Inc.
  • Spectrum Pharmaceuticals, Inc.

This activity is supported by a grant from AstraZeneca.

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Course summary
Available credit: 
  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Pharmacist
  • 1.00 Physician
Course opens: 
Course expires: 
Event starts: 
08/12/2015 - 4:00pm EDT
Event ends: 
08/12/2015 - 5:00pm EDT

Kathleen Horst, MD
Stanford Cancer Institute

Melinda Telli, MD
Stanford Cancer Institute

This activity is approved for AMA PRA Category 1 Credit(s)™. Nursing and pharmacy (ACPE) credits are also provided. View complete accreditation information

Available Credit

  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Pharmacist
  • 1.00 Physician


Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Reader or other PDF reader software for certificate viewing/printing